Tag: Lexicon Pharmaceuticals
10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community
As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …
READ MORE
December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community
Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple…
READ MORE September Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!
Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs…
READ MORE
Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial
Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…
READ MORE
10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORE
Luncheon with Carcinoid and Neuroendocrine Tumor Experts in New York City
Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome
Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…
READ MORE
Discover Something New in Carcinoid Syndrome
For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…
READ MORE
Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…
READ MORE
Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment
Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA). LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…
READ MORE
